Skip to main content
. 2017 Jun 19;14(2):2089–2096. doi: 10.3892/ol.2017.6420

Table I.

Baseline demographics of all patients included in the present study.

Characteristic Patients (n=174)
Sex
  Male 90.2% (157/174)
  Female 9.8% (17/174)
Age, years 55 (19–85)
Ascites 66.1% (115/174)
Encephalopathy 2.9% (5/174)
Karnofsky performance status 60 (20–90)
Laboratory parameters
  Leukocytes, ×109 cells/l 6.84 (1.84–25.09)
  Neutrophils, ×109 cells/l 4.89 (1.11–22.44)
  ALC, ×109 cells/l 1.23 (0.32–4.18)
  AMC, ×109 cells/l 0.60 (0.08–3.85)
  Hemoglobin, g/l 115.3 (56.0–177.0)
  Platelets, ×109 cells/l 156.3 (4.0–503.0)
  LMR 2.57 (0.39–7.0)
  ≤2.22 49.4% (86/174)
  >2.22 50.6% (88/174)
3-Month mortality rate, % 59.2% (103/174)
6-Month mortality rate, % 74.1% (129/174)
Child-Pugh grade
  0 20.7% (36/174)
  1 44.8% (78/174)
  2 34.5% (60/174)
TNM stage
  I 9.8% (17/174)
  II 11.5% (20/174)
  III 56.3% (98/174)
  IV 22.4% (39/174)
Lymph node metastasis 30.5% (53/174)
Distant metastases 20.7% (36/174)
Portal vein thrombosis 72.4% (126/174)
NCCN-TNM
  T1 10.9% (19/174)
  T2 13.8% (24/174)
  T3-T4 75.3% (131/174)

ALC, absolute lymphocyte count; AMC, absolute monocyte count; LMR, lymphocyte-to-monocyte ratio; NCCN, National Comprehensive Cancer Network; TNM, tumor-node-metastasis.